A Agilent Technologies Inc.

Agilent Technologies Extends Biopharma Portfolio with Advanced Mass Spec System

Agilent Technologies Inc. (NYSE: A) introduces the latest addition to its portfolio of solutions for biopharmaceutical labs: the Agilent 6545XT AdvanceBio LC/Q-TOF MS System.

Optimized to address analytical workflows commonly used in biopharma, the new LC/Q-TOF MS system combines high-performance liquid chromatography with robust quadrupole time-of-flight mass spectrometry and data-analysis tools. A research-grade system, the 6545XT is designed to deliver superior results to scientists seeking to characterize biomolecules that could be the basis for new therapeutics.

“Agilent is committed to providing complete workflow solutions to the biopharma industry that address critical areas for biotherapeutic development,” said Monty Benefiel, Agilent vice president and general manager of the company's Mass Spectrometry Division. “Agilent solutions built around the 6545XT enable scientists to characterize biomolecule structure and function more efficiently than ever, resulting in reduced time to market and improved drug efficacy.”

The 6545XT has also been optimized for use in profiling intact proteins, mapping peptides and identifying post-translational modifications.

Additionally, Agilent’s solutions for these types of workflows are further enhanced by the Agilent AdvanceBio LC column portfolio including the introduction today of a new column: the AdvanceBio Peptide Plus column. This column is designed for LC/MS peptide separations utilizing our unique superficially porous particle technology.

These new products complement and optimize Agilent’s existing biopharma portfolio, which includes products for sample preparation, separation, detection and analysis.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

EN
07/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch